Nature Reviews Drug Discovery 2018-03-28

George Yancopoulos

Index: 10.1038/nrd.2018.41

Full Text: HTML

Abstract

George Yancopoulos George Yancopoulos, Published online: 28 March 2018; doi:10.1038/nrd.2018.41George Yancopoulos, CSO of Regeneron, discusses his 30 years at Regeneron, the company's evolving growth plans and the recent launch of a precompetitive collaboration to sequence 500,000 UK Biobank exomes.

Latest Articles:

INFORMED: an incubator at the US FDA for driving innovations in data science and agile technology

2018-04-06

[10.1038/nrd.2018.34]

The gastroesophageal cancer drug market

2018-04-03

[10.1038/nrd.2018.35]

Antivirals: Topical therapy for ocular herpes

2018-03-28

[10.1038/nrd.2018.47]

Infectious disease: Virus-based tuberculosis vaccine

2018-03-28

[10.1038/nrd.2018.50]

Immunotherapy: iPSC-based cancer vaccine

2018-03-28

[10.1038/nrd.2018.48]

More Articles...